Cargando…

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study

INTRODUCTION: No controlled clinical trials had studied the role of maraviroc (MRV) in fully suppressed patients [1]. MATERIALS AND METHODS: MRV-cohort is an observational, retrospective, multicentric (27 sites) large cohort study of patients starting MRV in clinical practice under different circums...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jesús Pérez Elías, María, Arroyo, David, Diaz, Alberto, Herrero, Cristina, Martinez-Dueñas, Loreto, Moreno, Ana, Hernández-Quero, Jose, Podzamcer, Daniel, Gomez-Ayerbe, Cristina, Luis Casado, Jose, Zamora, Javier, Rivero, Antonio, Moreno, Santiago, María Llibre, Josep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P268
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225361/ https://www.ncbi.nlm.nih.gov/pubmed/25397544 http://dx.doi.org/10.7448/IAS.17.4.19800

Ejemplares similares

Le scanner thoracique lève le voile sur les séquelles pulmonaires du COVID
por: Ben Rhouma, C., et al.
Publicado: (2022)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc
por: Bernal, Enrique, et al.
Publicado: (2014)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
por: Kawana-Tachikawa, Ai, et al.
Publicado: (2014)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS)
por: Gomez-Ayerbe, Cristina, et al.
Publicado: (2014)

The role of SEAD project intervention in viral suppression of HIV/AIDS patients with follow-up and adherence barriers
por: Elías Casado, L, et al.
Publicado: (2012)

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients
por: Piconi, Stefania, et al.
Publicado: (2016)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
por: Chan, Phylinda L. S., et al.
Publicado: (2010)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity
por: Legnani, L., et al.
Publicado: (2016)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

Comparison of routine versus targeted HIV testing strategies: coverage and estimated missed infections in emergency room and primary care centre
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hv05646p2mep75h5jlncc370ik